SCHEMBL7643373

SCHEMBL7643373

CC(=N)Nc1ccc2oc(-c3ccc(-n4ccnc4)cc3)c(O)c(=O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 1/20 0.44
MAPT P10636 5/20 0.44
CYP3A4 P08684 4/20 0.44
KMT2A Q03164 4/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP2C9 P11712 1/20 0.44
CSNK2A2 P19784 3/20 0.42
CSNK2B P67870 3/20 0.42
CSNK2A1 P68400 3/20 0.42
TP53 P04637 3/20 0.42
TNIK Q9UKE5 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
BAZ2B Q9UIF8 1/20 0.38
LMNA P02545 1/20 0.38
RET P07949 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL926326 0.99 MKNK2 (0.43) MKNK2MAPTCYP3A4KMT2AKDM4E
SCHEMBL7642120 0.91 TNIK (0.48) MKNK2MAPTCYP3A4KMT2AKDM4E
SCHEMBL7638451 0.90 DHFR (0.44) MKNK2MAPTCYP3A4KMT2AKDM4E
SCHEMBL7637778 0.86 CSNK2A2 (0.40) MKNK2MAPTCYP3A4KMT2AKDM4E
SCHEMBL7638899 0.85 MKNK2 (0.40) MKNK2MAPTCYP3A4KMT2AKDM4E
Hydrochloric Acid SCHEMBL928145 0.83 MKNK2 (0.38) MKNK2MAPTCYP3A4KMT2AKDM4E
SCHEMBL7640696 0.82 CYP19A1 (0.43) CYP3A4PORCN
SCHEMBL7639410 0.79 CSNK2A2 (0.66) MAPTCYP3A4KMT2AKDM4EMEN1
SCHEMBL7643991 0.78 MEN1 (0.58) MAPTCYP3A4KMT2AKDM4EMEN1
SCHEMBL7642172 0.78 MAPT (0.49) MKNK2MAPTCYP3A4KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 US disclosed
US-8372866-B2 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain ROTTAPHARM S.P.A. (IT) 2013-02-12 US disclosed
EP-2268628-B1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM SPA (IT) 2012-05-16 EP disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 US disclosed
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2011-01-06 US disclosed
WO-2009109230-A1 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN ROTTAPHARM S.P.A. (IT) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003861-A1 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN NAT1, AADAC, OPRL1 MKNK2 1696/4885MAPT 4791/4885CYP3A4 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.